Bioseparation the set of technologies that isolates and purifies biological molecules such as proteins, antibodies, nucleic acids and viral vectors has quietly become one of the most important backbones of modern biopharma. As biologics, cell & gene therapies, and mRNA platforms scale from lab benches to manufacturing lines, demand for faster, higher-yield, and regulatory-compliant separation systems has exploded. This blog breaks down the market today, the forces driving it, the technologies and players to watch, and where the next opportunities lie.
Estimates vary by source, but most market studies agree the bioseparation systems market is substantial and growing at a high single-digit to low double-digit CAGR. The global market for bioseparation systems was valued at an estimated $30.6 billion in 2024 and is slated to reach $45.1 billion by the end of 2030.
Explosion of biologics & advanced therapies - Monoclonal antibodies, recombinant proteins, viral vectors and cell-based therapies all require complex downstream purification steps; more biologics = more separation gear.
Shift from batch to continuous and single-use manufacturing - Manufacturers are adopting continuous processes and single-use consumables to reduce contamination risk and speed time-to-market; that pushes demand for adaptable membrane and chromatography solutions.
Regulatory and purity expectations - Stricter impurity limits and the need for consistent, validated processes favor high-performance separation platforms.
Cost pressure & efficiency - Downstream steps historically make up a large share of production cost for biologics; technologies that increase yield and cut cycle time are commercially attractive.